Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
”Cancer-associated thrombosis (CAT) remains one of the highest-risk VTE settings, where we constantly balance recurrent VTE prevention against bleeding risk.
API-CAT evaluated whether a reduced-dose apixaban strategy could maintain efficacy while improving safety during extended anticoagulation.
The trial showed that a lower dose of apixaban (2.5 mg BID) was non-inferior to the standard dose (5 mg BID) for preventing recurrent VTE in patients with active cancer, and it was associated with less bleeding.”
Read the full article here.
Article: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez et al., for the API-CAT Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 16, 2026, 09:57Nathan Connell: A Regional Approach to Advancing Contemporary Hemophilia A Care
-
Sep 16, 2026, 09:20Mengistu Abate Belay: Bridging the Gap in Anemia Prevention During Pregnancy
-
Sep 16, 2026, 09:09Younes Kalakhy: When Normal Coagulation Tests Miss von Willebrand Disease
-
Sep 16, 2026, 09:00Test Your Knowledge of Warm Autoimmune Hemolytic Anemia – ASH Education
-
Sep 16, 2026, 08:28Jean Nakhle: Uncovering How Excess Cysteine Drives Cell Death
-
Sep 16, 2026, 08:20Heghine Khachatryan: Arterial and Venous Thrombosis May Require Different Approaches in Neonates
-
Sep 16, 2026, 07:57Tammuella Chrisentery-Singleton: Standing on the Shoulders of Giants in Hemophilia Care
-
Sep 16, 2026, 07:33Jakob Werner Hansen: Nordic VEX AZA Trial Reaches an Important Milestone
-
Sep 16, 2026, 06:54Jonathan Furniss: The Platelet Response That Helps Drive Tissue Repair